AR121804A1 - Preparación sólida y método para producir la misma - Google Patents
Preparación sólida y método para producir la mismaInfo
- Publication number
- AR121804A1 AR121804A1 ARP210100940A ARP210100940A AR121804A1 AR 121804 A1 AR121804 A1 AR 121804A1 AR P210100940 A ARP210100940 A AR P210100940A AR P210100940 A ARP210100940 A AR P210100940A AR 121804 A1 AR121804 A1 AR 121804A1
- Authority
- AR
- Argentina
- Prior art keywords
- mass
- parts
- solid preparation
- producing
- granule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción proporciona una preparación sólida que contiene 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N-(metilsulfonil)acetamida (nombre genérico; selexipag); y un método para producir la preparación sólida. La preparación sólida comprende un gránulo que contiene (A) selexipag, (B) almidón, y (C) al menos un aglutinante seleccionado del grupo que consiste en hidroxipropil celulosa e hipromelosa, en donde el componente (B) está presente en una cantidad de 20 partes en masa o más (excluyendo el rango de 30,2 a 30,4 partes en masa) por 100 partes en masa del gránulo, y el componente (C) está presente en una cantidad de 4 partes en masa o menos por 100 partes en masa del gránulo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020071233 | 2020-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121804A1 true AR121804A1 (es) | 2022-07-13 |
Family
ID=78023633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100940A AR121804A1 (es) | 2020-04-10 | 2021-04-09 | Preparación sólida y método para producir la misma |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP6989064B1 (es) |
AR (1) | AR121804A1 (es) |
TW (1) | TW202203924A (es) |
WO (1) | WO2021206159A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ742784A (en) * | 2015-12-02 | 2024-08-30 | Nippon Shinyaku Co Ltd | Pharmaceutical composition containing 2-{ 4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy} -n- (methylsulfonyl)acetamide |
KR20200088382A (ko) * | 2017-11-16 | 2020-07-22 | 니뽄 신야쿠 가부시키가이샤 | 방출 제어 제제 |
CA3091584A1 (en) * | 2018-02-21 | 2019-08-29 | Nippon Shinyaku Co., Ltd. | Granular composition, production method for granular composition, and dissolution property improvement method for granular composition |
-
2021
- 2021-04-09 TW TW110112900A patent/TW202203924A/zh unknown
- 2021-04-09 AR ARP210100940A patent/AR121804A1/es unknown
- 2021-04-09 WO PCT/JP2021/014987 patent/WO2021206159A1/ja active Application Filing
- 2021-04-09 JP JP2021540136A patent/JP6989064B1/ja active Active
- 2021-11-22 JP JP2021189321A patent/JP2022016561A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021206159A1 (ja) | 2021-10-14 |
JP6989064B1 (ja) | 2022-01-05 |
JPWO2021206159A1 (es) | 2021-10-14 |
TW202203924A (zh) | 2022-02-01 |
JP2022016561A (ja) | 2022-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007298751B2 (en) | Pharmaceutical compositions containing rosuvastatin calcium | |
KR102072371B1 (ko) | 7-[4-(4-벤조[b]티오펜-4-일-피페라진-1-일)부톡시]-1H-퀴놀린-2-온 또는 그 염을 함유하는 정제 | |
DOP2022000110A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
BRPI0607869A2 (pt) | hidroxietilcelulose em bloco, derivados da mesma, processos de fabricação e usos da mesma | |
BRPI0518553A2 (pt) | composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada | |
BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
BR112017023764A2 (pt) | derivados de ciclohexano substituído por amido | |
BR112021022335A2 (pt) | Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer | |
BR112022019057A2 (pt) | Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune | |
EA201992074A1 (ru) | Фармацевтическая композиция, содержащая селексипаг | |
BRPI0717123B8 (pt) | cápsulas rígidas de hidroxipropil metil celulose e processo de fabricação | |
NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
RU2012103538A (ru) | Композиции и способы ингибирования пути jak | |
HN2008000240A (es) | Agentes voluminizadores | |
ECSP22040921A (es) | Composición farmacéutica que comprende selexipag | |
AR121804A1 (es) | Preparación sólida y método para producir la misma | |
CR20210686A (es) | Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida | |
CO2024013531A2 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
BR112022020609A2 (pt) | Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo | |
CO2023005942A2 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
BR112022013280A2 (pt) | Composição farmacêutica contendo regorafenib e um agente estabilizante | |
CO2022003346A2 (es) | Composiciones de recubrimiento de semillas | |
BR112022014772A2 (pt) | Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas |